Tumor infiltrating B-cells are increased in prostate cancer tissue

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Woo, Jason R ^a   Liss, Michael A ^a   Muldong, Michelle T ^a,c   Palazzi, Kerrin ^a   Strasner, Amy ^a,c   Ammirante, Massimo ^a   Varki, Nissi ^a,c   Shabaik, Ahmed ^a   Howell, Stephen ^b,c   Kane, Christopher J ^a,c   Karin, Michael ^a,c   Jamieson, Christina A M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

B cells; CD20; CRPC: castrate resistant prostate cancer; D'Amico risk stratification; Digital IHC image analysis; Immunohistochemistry; Prostatectomy; TIL: tumor infiltrating lymphocyte

Indexed keywords

ANIMALS; ANTIGENS, CD20; B-LYMPHOCYTES; CELL COUNT; DEMOGRAPHY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84893203731     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-30     Document Type: Article

References (33)

1. May KF, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer immunotherapy. Clin Cancer Res 2011, 17:5233-5238. 10.1158/1078-0432.CCR-10-3402, 3263933, 21700764.
2. Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD. Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Lab Invest 2009, 89:142-151. 10.1038/labinvest.2008.123, 19079323.
3. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2013, Epub ahead of print].
4. Schmidt M, Bohm D, von Torne C, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68:5405-5413. 10.1158/0008-5472.CAN-07-5206, 18593943.
5. Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012, 72:1070-1080. 10.1158/0008-5472.CAN-11-3218, 3306813, 22266112.
6. Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012, 18:3281-3292. 10.1158/1078-0432.CCR-12-0234, 22553348.
7. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227. 10.1158/1078-0432.CCR-08-0133, 18698040.
8. Fujii T, Shimada K, Asai O, et al. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology 2013, 80:119-126. 10.1159/000342396, 23328608.
9. Gannot G, Richardson AM, Rodriguez-Canales J, et al. Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer. Am J Cancer Res 2011, 1:120-127. 3180108, 21969236.
10. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007, 446:690-694. 10.1038/nature05656, 17377533.
11. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305. 10.1038/nature08782, 2866639, 20220849.
12. Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M. An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 2013, 27:1435-1440. 10.1101/gad.220202.113, 3713424, 23796898.
13. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974. 10.1001/jama.280.11.969, 9749478.
14. Mitra N, Banda K, Altheide TK, Schaffer L, Johnson-Pais TL, Beuten J, Leach RJ, Angata T, Varki N, Varki A. SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. J Biol Chem 2011, 286(26):23003-23011. 10.1074/jbc.M111.244152, 3123068, 21555517.
15. Linnebacher M. Tumor-infiltrating B, cells come into vogue. World J Gastroenterol 2013, 19:8-11. 10.3748/wjg.v19.i1.8, 3542760, 23326156.
16. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
17. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011, 105:93-103. 10.1038/bjc.2011.189, 3137407, 21629244.
18. Flammiger A, Bayer F, Cirugeda-Kuhnert A, et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 2012, 120:901-908. 10.1111/j.1600-0463.2012.02924.x, 23009114.
19. Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol 2009, 86(2):108-113. 10.1016/j.yexmp.2008.11.010, 19111537.
20. Moser PL, Brunner A, Horninger W, Bartsch G, Mikuz G. Correlation between inflammatory cells in prostate biopsies and elevated PSA levels in a PSA screening population. Urology 2002, 59:68-72.
21. Kärjä V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005, 25:4435-4438.
22. Blumenfeld W, Tucci S, Narayan P. Incidental lymphocytic prostatitis, Selective involvement with nonmalignant glands. Am J Surg Pathol 1992, 16:975-981. 10.1097/00000478-199210000-00008, 1415905.
23. Ebelt K, Babaryka G, Figel AM, et al. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008, 68:1-10. 10.1002/pros.20661, 17948280.
24. Becker RL. Standardization and quality control of quantitative microscopy in pathology. J Cell Biochem Suppl 1993, 17G:199-204.
25. Franklin WA, Bibbo M, Doria MI, et al. Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system. Anal Quant Cytol Histol 1987, 9:279-286.
26. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997, 45(11):1559-1565. 10.1177/002215549704501112, 9358857.
27. Braun M, Kirsten R, Rupp NJ, et al. Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol 2013, 28:605-610.
28. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 2004, 91:541-543. 10.1038/sj.bjc.6601943, 2409839, 15266325.
29. Irani JGJ, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 1999, 54:467-472. 10.1016/S0090-4295(99)00152-1, 10475356.
30. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994, 30A:1797-1803.
31. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. IMPACT study investigators, sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422. 10.1056/NEJMoa1001294, 20818862.
32. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11(11):805-812. 10.1038/nrc3153, 3426440, 22020206.
33. Slovin SF. Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. Immunotherapy 2013, 5(12):1347-1355. 10.2217/imt.13.140, 24283845.